Vancive Medical Technologies Signs Agreement with Carefusion for Chlorhexidine Gluconate Antimicrobial Adhesive Dressing Technology

Exclusive agreement in North America marks first line of vascular access dressings from CareFusion.

On the opening day of Medica and Compamed in Germany, Vancive Medical Technologies and CareFusion Corporation have announced an exclusive agreement in the United States, Canada and Mexico for the licensing and distribution of Vancive’s BeneHold (trademarked) chlorhexidine gluconate (CHG) antimicrobial adhesive technology for applications in vascular access.

Under the agreement, CareFusion will market Vancive’s unique antimicrobial adhesive technology used with transparent dressings that are ideally suited for protection of catheter insertion sites. The first product received 510(k) clearance from the US Food and Drug Administration (FDA) in September 2012 and will be co-branded under CareFusion’s new ChloraShield brand.

“We are excited about this collaboration and believe it is an excellent opportunity to combine the unique capabilities of each company,” said Howard Kelly, president and general manager of Vancive Medical Technologies. “By bringing together the considerable infection prevention expertise at CareFusion and Vancive’s cutting-edge technologies, we will provide innovative solutions to the vascular access market.”

CareFusion and Vancive are working together to develop a comprehensive line of dressing products that incorporate the BeneHold CHG antimicrobial Adhesive Technology to meet the specific needs associated with many types of vascular access procedures. CareFusion expects to commercialise these offerings during the company’s fiscal third quarter, which begins in April.

“The collaboration with Vancive Medical Technologies and the new ChloraShield line of dressings are a perfect fit with our leadership in CHG products,” said Jim Leitl, senior vice president and general manager of Medical Specialties at CareFusion. “These innovative vascular access dressings extend our clinically differentiated infection prevention and vascular access product portfolios, allowing us to create greater value for our customers.”

BeneHold is a trademark of Avery Dennison Corporation. ChloraShield is a trademark of CareFusion Corporaiton.

In terms of Vancive's exhibits at the Medica show, Vancive will be showing a range of products, including new digital healthcare solutions.

One of these will bethe Metria trademarked Informed Health technology* platform (see image), a portfolio of products for physiological monitoring for a variety of health, wellness and clinical applications. These products are disposable, adhere to the body with a skin-friendly adhesive, and can be used while showering or exercising.

* Metria Informed Health products includes technologies from Proteus Digital Health and Bodymedia, Inc. Metria products have not been cleared by regulatory agencies.

According to Deepak Prakash, global director of marketing, Vancive Medical Technologies, several new Metria developments are on tap for 2014.

“We look forward to the commercial launch of our first product using this technology, Metria IH1, intended for various lifestyle management applications,” says Prakash. “It collects and reports multiple lifestyle parameters including activity and activity levels, sleep, and calorie expenditure, all in a unique, convenient form factor.”

“Another exciting application we are exploring with this technology is cardiac diagnostics,” Prakash continues. “This technology can also be configured to allow capture and transmission of an electrocardiogram that can be used, for example, in cardiac rhythm analyses. The interest level for the Metria platform is high in the US and abroad, as it can address multiple markets and use cases. We expect to announce these advancements in 2014.”

Vancive is exhibiting at Medica 2013 on November 20-23, 2013, in Düsseldorf, Germany, at booths 6H07 and 15B57.

To learn more, please visit vancive.averydennison.com.